Reporting and notification of adverse events in orthopaedics

Journal of the American Academy of Orthopaedic Surgeons

Volumn 18, Issue 4, 2010, Pages 193-198

  Mihalko, William M ^a   Seth Greenwald, A ^b   Lemons, Jack ^c   Kirkpatrick, John ^d  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b Orthopaedic Research Laboratories   (United States)

^c Mayo Clinic College of Medicine   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77951241498     PISSN: 1067151X     EISSN: None     Source Type: Journal    
DOI: 10.5435/00124635-201004000-00002     Document Type: Article

References (20)

1. Alder H: Safe Medical Devices Act of 1990: Current hospital requirements and recommended actions. Healthc Facil Manag Ser 1993 Sep:1-34.
2. Kessler DA: Changing the culture of medicine: The FDA's MED Watch program. Acad Med 1993; 68: 776-777.
3. Kessler DA: Introducing MEDWatch: A new approach to reporting medication and device adverse effects and product problems. J Am Podiatr Med Assoc 1994; 84: 35-38.
4. Lewis LD, Nierenberg DW: Adverse drug reactions, Med Watch reporting and medical student education. Pharmacoepidemiol Drug Saf 2003; 12: 93-95.
5. Rosebraugh CJ, Tsong Y, Zhou F, et al: Improving the quality of adverse drug reaction reporting by 4th-year medical students. Pharmacoepidemiol Drug Saf 2003; 12: 97-101. (Pubitemid 36304759)
6. Meadows M: Med Watch: Managing risks at the FDA. FDA Consum 2003; 37: 10-11.
7. Bloebaum RD, Ferguson RP, Neff CM, Van Gorp C, Woolley DL, Hofmann AA: Bone viability determination in human cancellous bone from patients undergoing revision hip arthroplasty. J Arthroplasty 2004; 19: 745-750. (Pubitemid 39179784)
8. Arthroscopic shavers: Ongoing safety review. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm170730.htm Accessed January 21, 2010.
9. Duran C, Sirvanci M, Aydoǧan M, Ozturk E, Ozturk C, Akman C: Pulmonary cement embolism: A complication of percutaneous vertebroplasty. Acta Radiol 2007; 48: 854-859. (Pubitemid 47551925)
10. Knudsen JF, Sokol GH: Potential glucosamine-warfarin interaction resulting in increased international normalized ratio: Case report and review of the literature and Med Watch database. Pharmacotherapy 2008; 28: 540-548.
11. Wood JJ, Malek MA, Frassica FJ, et al: Autologous cultured chondrocytes: adverse events reported to the United States Food and Drug Administration. J Bone Joint Surg Am 2006; 88: 503-507.
12. Wang S, Zinderman C, Wise R, Braun M: Infections and human tissue transplants: Review of FDA Med Watch reports 2001-2004. Cell Tissue Bank 2007; 8: 211-219.
13. Love L, Couig MP: The Med Watch Program. J Toxicol Clin Toxicol 1999; 37: 803-807.
14. White GG: Med Watch program, Int J Trauma Nurs 1998; 4: 100-103.
15. Landow L: Monitoring adverse drug events: The Food and Drug Administration Med Watch reporting system. Reg Anesth Pain Med 1998; 23(6 suppl 2): 190-193.
16. Kirkpatrick J: MedWatch: Your link to adverse event reporting. AAOS Now Mar/Apr 2007; 1: 45-46. Available at: http://www.aaos.org/news/bulletin/ marapr07/reimbursement4.asp. Accessed January 21, 2010.
17. FDA Public Health Web Notification: Complications related to the use of bone cement and bone void fillers in treating compression fractures of the spine. Available at: http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ PublicHealthNotifications/ucm062126.htm. Accessed January 21, 2010.
18. Bone cement in vertebroplasty and kyphoplasty procedures. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm154563.htm. Accessed January 21, 2010.
19. St. Gobain Desmarquest Zirconia Ceramic Femoral Head recall: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm172706.htm. Accessed January 21, 2010.
20. Piconi C, Maccauro G, Pilloni L, Burger W, Muratori F, Richter HG: On the fracture of a zirconia ball head. J Mater Sci Mater Med 2006; 17: 289-300.